VVOS (Vivos Therapeutics) Short-Term Debt: $7.30 Mil (As of Mar. 2026)


VVOS Vivos Therapeutics Inc VVOS
41 GF Score
Price $0.48
GF Value $1.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vivos Therapeutics Short-Term Debt?

Vivos Therapeutics VVOS +6.47% 41 Short-Term Debt is $7.30 Mil as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

Vivos Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2026 was $7.30 Mil.

Vivos Therapeutics's quarterly Short-Term Debt increased from Sep. 2025 ($0.34 Mil) to Dec. 2025 ($8.35 Mil) but then declined from Dec. 2025 ($8.35 Mil) to Mar. 2026 ($7.30 Mil).

Vivos Therapeutics's annual Short-Term Debt stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($8.35 Mil).

Vivos Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Vivos Therapeutics Short-Term Debt Related Terms

Vivos Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Vivos Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Therapeutics Short-Term Debt Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 1.27 0.00 0.00 0.00 8.35

Vivos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.16 0.34 8.35 7.30
VVOS
41GF Score
Vivos Therapeutics Inc VVOS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $7.30 Mil mean?
Vivos Therapeutics (VVOS) has a Short-Term Debt of $7.30 Mil as of Mar. 2026.
Is Vivos Therapeutics' Short-Term Debt too high?
Vivos Therapeutics' current Short-Term Debt is $7.30 Mil. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Short-Term Debt compare to XAIR and TNON?
Vivos Therapeutics' Short-Term Debt of $7.30 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Vivos Therapeutics's current Short-Term Debt is $7.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.48 — trading 58.4% below its estimated fair value. The current Short-Term Debt is $7.30 Mil. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Short-Term Debt is $7.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivos Therapeutics (VVOS) Overvalued in 2026?

Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued. The current stock price of $0.48 is trading 58.4% below its estimated GF Value™ of $1.15. GuruFocus considers Vivos Therapeutics to be Possible Value Trap.

Key valuation signals for VVOS:

  • Short-Term Debt: $7.30 Mil
  • GF Value™: $1.15 vs. price of $0.48 (58.4% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivos Therapeutics Business Description

Address 7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score

Get the complete analysis for VVOS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price
$1.15
GF Value